Thymic malignancies: From clinical management to targeted therapies

Journal of Clinical Oncology

Volumn 29, Issue 36, 2011, Pages 4820-4827

  Kelly, Ronan J ^a   Petrini, Iacopo ^a   Rajan, Arun ^a   Wang, Yisong ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; AFLIBERCEPT; BELINOSTAT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; IFOSFAMIDE; IMATINIB; MEPREDNISONE; OCTREOTIDE; PACLITAXEL; PEMETREXED; PENTETATE INDIUM IN 111; PHA 848125 AC; PREDNISONE; PYRAZOLOQUINAZOLINE; QUINAZOLINE DERIVATIVE; SARACATINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; AUTOIMMUNE DISEASE; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORPHOLOGY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG TARGETING; ETHNIC DIFFERENCE; FATIGUE; GENE MUTATION; GENETIC HETEROGENEITY; GENOME ANALYSIS; HISTOLOGY; HUMAN; IMMUNOREACTIVITY; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SCINTIGRAPHY; SEX DIFFERENCE; SURVIVAL TIME; SYSTEMATIC REVIEW; THYMOCYTE; THYMOMA; THYMUS CANCER; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASM STAGING; OCTREOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, TRKA; THYMUS NEOPLASMS;

EID: 84555197165     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.0487     Document Type: Review

References (102)

1. Margaritora S, Cesario A, Cusumano G, et al.: Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 89:245-252, 2010; discussion 252
2. Engels EA, Pfeiffer RM: Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 105:546-551, 2003 (Pubitemid 36578561)
3. Evoli A, Punzi C, Marsili F, et al.: Extrathymic malignancies in patients with thymoma. Ann Oncol 15:692-693, 2004
4. Pan CC, Chen PC, Wang LS, et al.: Thymoma is associated with an increased risk of second malignancy. Cancer 92:2406-2411, 2001
5. Loehrer PJ Sr, Wang W, Johnson DH, et al.: Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 22:293-299, 2004 (Pubitemid 41095094)
6. Engels EA: Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5:S260-S265, 2010 (suppl 4)
7. Strollo DC, Rosado de Christenson ML, Jett JR: Primary mediastinal tumors: Part 1. Tumors of the anterior mediastinum. Chest 112:511-522, 1997
8. Phillips LH 2nd, Torner JC, Anderson MS, et al.: The epidemiology of myasthenia gravis in central and western Virginia. Neurology 42:1888-1893, 1992
9. Gadalla SM, Rajan A, Pfeiffer R, et al.: A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 128:2688-2694, 2011
10. Vukmanović S, Bevan MJ, Hogquist KA: The specificity of positive selection: MHC and peptides. Immunol Rev 135:51-66, 1993 (Pubitemid 23342999)
11. Masaoka A, Monden Y, Nakahara K, et al.: Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485-2492, 1981 (Pubitemid 12228012)
12. Koga K, Matsuno Y, Noguchi M, et al.: A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 44: 359-367, 1994 (Pubitemid 24153752)
13. Kuo TT: Tumours of the thymus, in Travis WD, Brambilla E, Muller-Hermelink HK, et al. (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France, IARC Press, 2004, pp 146-248
14. Moran CA, Suster S: On the histologic heterogeneity of thymic epithelial neoplasms: Impact of sampling in subtyping and classification of thymomas. Am J Clin Pathol 114:760-766, 2000 (Pubitemid 33051913)
15. Chen G, Marx A, Chen WH, et al.: New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer 95:420-429, 2002 (Pubitemid 34787609)
16. Herens C, Radermecker M, Servais A, et al.: Deletion (6)(p22p25) is a recurrent anomaly of thymoma: Report of a second case and review of the literature. Cancer Genet Cytogenet 146:66-69, 2003 (Pubitemid 37117436)
17. Kuhn E, Wistuba II: Molecular pathology of thymic epithelial neoplasms. Hematol Oncol Clin North Am 22:443-455, 2008 (Pubitemid 351726405)
18. Ionescu DN, Sasatomi E, Cieply K, et al.: Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 103:630-636, 2005
19. Suzuki E, Sasaki H, Kawano O, et al.: Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 36:351-356, 2006 (Pubitemid 44043923)
20. Henley JD, Cummings OW, Loehrer PJ Sr: Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130:222-224, 2004 (Pubitemid 38553631)
21. Hayashi Y, Ishii N, Obayashi C, et al.: Thymoma: Tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 426:43-50, 1995
22. Pan CC, Chen PC, Wang LS, et al.: Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 43:165-172, 2003 (Pubitemid 36963161)
23. Nakagawa K, Matsuno Y, Kunitoh H, et al.: Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 128:140-144, 2005 (Pubitemid 40994465)
24. Pan CC, Chen PC, Chiang H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375-381, 2004 (Pubitemid 38325248)
25. Penzel R, Hoegel J, Schmitz W, et al.: Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 105:494-498, 2003 (Pubitemid 36578553)
26. Tateyama H, Eimoto T, Tada T, et al.: p53 protein expression and p53 gene mutation in thymic epithelial tumors: An immunohistochemical and DNA sequencing study. Am J Clin Pathol 104:375-381, 1995
27. Chen FF, Yan JJ, Jin YT, et al.: Detection of bcl-2 and p53 in thymoma: Expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol 27:1089-1092, 1996
28. Pich A, Chiarle R, Chiusa L, et al.: p53 expression and proliferative activity predict survival in non-invasive thymomas. Int J Cancer 69:180-183, 1996 (Pubitemid 26233295)
29. Weirich G, Schneider P, Fellbaum C, et al.: p53 alterations in thymic epithelial tumours. Virchows Arch 431:17-23, 1997 (Pubitemid 27338598)
30. Hirabayashi H, Fujii Y, Sakaguchi M, et al.: P16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 73:639-644, 1997 (Pubitemid 127483057)
31. Zettl A, Ströbel P, Wagner K, et al.: Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol 157:257-266, 2000 (Pubitemid 30642585)
32. Girard N, Shen R, Guo T, et al.: Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 15:6790-6799, 2009
33. Inoue M, Marx A, Zettl A, et al.: Chromosome 6 suffers frequent and multiple aberrations in thymoma. Am J Pathol 161:1507-1513, 2002
34. Zhou R, Zettl A, Ströbel P, et al.: Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol 159:1853-1860, 2001 (Pubitemid 33062527)
35. Inoue M, Starostik P, Zettl A, et al.: Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 63:3708-3715, 2003 (Pubitemid 36793056)
36. Nabarra B, Pontoux C, Godard C, et al.: Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice). Int J Exp Pathol 86:397-413, 2005 (Pubitemid 41746378)
37. Stefanaki K, Rontogianni D, Kouvidou CH, et al.: Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. Histopathology 30:549-555, 1997 (Pubitemid 27254944)
38. Oyama T, Osaki T, Mitsudomi T, et al.: p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med 1:823-826, 1998
39. Mineo TC, Ambrogi V, Mineo D, et al.: Longterm disease-free survival of patients with radically resected thymomas: Relevance of cell-cycle protein expression. Cancer 104:2063-2071, 2005 (Pubitemid 41579951)
40. Khoury T, Arshad A, Bogner P, et al.: Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and nonreceptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms. Chest 136:220-228, 2009
41. Hino N, Kondo K, Miyoshi T, et al.: High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer 76:1361-1366, 1997 (Pubitemid 27474980)
42. Gilhus NE, Jones M, Turley H, et al.: Oncogene proteins and proliferation antigens in thymomas: Increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 48: 447-455, 1995
43. Engel P, Francis D, Graem N: Expression of bcl-2 in fetal thymus, thymomas and thymic carcinomas: Association with p53 expression and review of the literature. APMIS 106:449-455, 1998 (Pubitemid 28252944)
44. Comin CE, Messerini L, Novelli L, et al.: KI-67 antigen expression predicts survival and correlates with histologic subtype in the WHO classification of thymic epithelial tumors. Int J Surg Pathol 12:395-400, 2004 (Pubitemid 39463508)
45. Hirose Y, Kondo K, Takizawa H, et al.: Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 64:155-159, 2009
46. Tsuji T, Ikeda H, Tsuchikawa T, et al.: Malignant transformation of thymoma in recipient rats by heterotopic thymus transplantation from HTLV-I transgenic rats. Lab Invest 85:851-861, 2005 (Pubitemid 41021294)
47. Scarpino S, Di Napoli A, Stoppacciaro A, et al.: Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 149:504-512, 2007 (Pubitemid 47256158)
48. Okumura M, Fujii Y, Shiono H, et al.: Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg 56:143-150, 2008 (Pubitemid 351514680)
49. Anderson MS, Venanzi ES, Klein L, et al.: Projection of an immunological self shadow within the thymus by the aire protein. Science 298:1395-1401, 2002 (Pubitemid 35346134)
50. Anderson MS, Venanzi ES, Chen Z, et al.: The cellular mechanism of Aire control of T cell tolerance. Immunity 23:227-239, 2005 (Pubitemid 41169291)
51. Finnish-German APECED Consortium: An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zincfinger domains. Nat Genet 17:399-403, 1997
52. Kekäläinen E, Tuovinen H, Joensuu J, et al.: A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis- ectodermal dystrophy. J Immunol 178:1208-1215, 2007 (Pubitemid 46095195)
53. Nagamine K, Peterson P, Scott HS, et al.: Positional cloning of the APECED gene. Nat Genet 17:393-398, 1997 (Pubitemid 27518386)
54. Burbelo PD, Browne SK, Sampaio EP, et al.: Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood 116:4848-4858, 2010
55. Liu JM, Wang LS, Huang MH, et al.: Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia. Cancer 109: 502-509, 2007 (Pubitemid 46195061)
56. Sasaki H, Fukai I, Kiriyama M, et al.: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Surg Today 33: 83-88, 2003 (Pubitemid 36269374)
57. Loehrer PJ Sr, Kim K, Aisner SC, et al.: Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an intergroup trial-The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12:1164-1168, 1994 (Pubitemid 24173929)
58. Fornasiero A, Daniele O, Ghiotto C, et al.: Chemotherapy for invasive thymoma: A 13-year experience. Cancer 68:30-33, 1991
59. Giaccone G, Ardizzoni A, Kirkpatrick A, et al.: Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14:814-820, 1996
60. Highley MS, Underhill CR, Parnis FX, et al.: Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 17:2737-2744, 1999 (Pubitemid 29415230)
61. Loehrer PJ Sr, Jiroutek M, Aisner S, et al.: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: An intergroup trial. Cancer 91: 2010-2015, 2001 (Pubitemid 32476364)
62. Grassin F, Paleiron N, Andre M, et al.: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 5:893-897, 2010
63. Lemma GL, Loehrer, PJ, Lee JW, et al.: A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 26:428s, 2008 (suppl; abstr 8018)
64. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al.: A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 24:383s, 2006 (suppl; abstr 7079)
65. Schmitt J, Loehrer PJ Sr: The role of chemotherapy in advanced thymoma. J Thorac Oncol 5:S357-S360, 2010 (suppl 4)
66. Yokoi K, Matsuguma H, Nakahara R, et al.: Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2:73-78, 2007 (Pubitemid 47163933)
67. Yoh K, Nishiwaki Y, Ishii G, et al.: Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62:316-320, 2008
68. Yamaguchi H, Soda H, Kitazaki T, et al.: Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 52:261-262, 2006
69. Kurup A, Burns M, Dropcho S, et al. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 23:381s, 2005 (suppl; abstr 7068)
70. Bedano PM, Perkins S, Burns M, et al.: A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 26:713s, 2008 (suppl; abstr 19087)
71. Giaccone G, Rajan A, Ruijter R, et al.: Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 4:1270-1273, 2009
72. Salter JT, Lewis D, Yiannoutsos PJ, et al.: Imatinib for the treatment of thymic carcinoma. J Clin Oncol 26:452s, 2008 (suppl; abstr 8116)
73. Giaccone G, Rajan A, Berman A, et al.: Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol 29:2052-2059, 2011
74. Farina G, Garassino MC, Gambacorta M, et al.: Response of thymoma to cetuximab. Lancet Oncol 8:449-450, 2007 (Pubitemid 46621774)
75. Palmieri G, Marino M, Salvatore M, et al.: Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12:757-761, 2007 (Pubitemid 46852818)
76. Cimpean AM, Raica M, Encica S, et al.: Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 190:238-245, 2008
77. Sasaki H, Yukiue H, Kobayashi Y, et al.: Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 31: 1038-1040, 2001 (Pubitemid 33141297)
78. Tomita M, Matsuzaki Y, Edagawa M, et al.: Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124:493-498, 2002
79. Isambert N, Freyer G, Zanetta S, et al.: A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: Preliminary results. J Clin Oncol 26:177s, 2008 (suppl; abstr 3599)
80. Bisagni G, Rossi G, Cavazza A, et al.: Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4:773-775, 2009
81. Li XF, Chen Q, Huang WX, et al.: Response to sorafenib in cisplatin-resistant thymic carcinoma: A case report. Med Oncol 26:157-160, 2009
82. Ströbel P, Bargou R, Wolff A, et al.: Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience. Br J Cancer 103:196-200, 2010
83. Fiedler W, Giaccone G, Lasch P, et al.: Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol 22:195-201, 2011
84. Ströbel P, Hartmann M, Jakob A, et al.: Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625-2626, 2004 (Pubitemid 38758557)
85. Heinrich MC, Maki RG, Corless CL, et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359, 2008
86. Girard N: Thymic tumors: Relevant molecular data in the clinic. J Thorac Oncol 5:S291-S295, 2010 (suppl 4)
87. Steele NL, Plumb JA, Vidal L, et al.: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804-810, 2008 (Pubitemid 351231163)
88. Reisine T, Bell GI: Molecular biology of somatostatin receptors. Endocr Rev 16:427-442, 1995
89. Krenning EP, Kwekkeboom DJ, Bakker WH, et al.: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716-731, 1993 (Pubitemid 23284773)
90. Lastoria S, Vergara E, Palmieri G, et al.: In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med 39:634-639, 1998 (Pubitemid 28175838)
91. Ferone D, van Hagen PM, van Koetsveld PM, et al.: In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 140:373-380, 1999 (Pubitemid 29011182)
92. Fuller PJ, Verity K: Somatostatin gene expression in the thymus gland. J Immunol 143:1015- 1017, 1989
93. Girard N, Teruya-Feldstein J, Payabyab EC, et al.: Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 5:1439-1446, 2010
94. Zucali PA, Petrini I, Lorenzi E, et al.: Insulinlike growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 116:4686- 4695, 2010
95. Haluska P, Shaw HM, Batzel GN, et al.: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007 (Pubitemid 47583908)
96. Rajan A, Berman AW, Kelly RJ, et al.: Phase II study of the insulin-like growth factor-1 receptor (IGF-1R) antibody cixutumumab (C) in patients (pts) with thymoma (T) and thymic carcinoma (TC). J Clin Oncol 28:e17525, 2010 (suppl)
97. Bothwell M: Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 18:223-253, 1995
98. Mineo TC, Mineo D, Onorati I, et al.: New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: A retrospective analysis. Ann Surg Oncol 17:3022-3029, 2010
99. Kim DJ, Yang WI, Kim SH, et al.: Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg 28: 611-616, 2005
100. Wakelee HA, Gubens MA, Burns M, et al.: A phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients with advanced thymic malignancies. Presented at International Thymic Malignancy Group Conference, New York, NY, May 5-6, 2010
101. Mineo TC, Ambrogi V, Baldi A, et al.: Recurrent intrathoracic thymomas: Potential prognostic importance of cell-cycle protein expression. J Thorac Cardiovasc Surg 138:40-45, 2009
102. Aisner SC, Dahlberg S, Hameed MR, et al.: Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: An Eastern Cooperative Oncology Group study. J Thorac Oncol 5:885-892, 2010